Literature DB >> 9784363

Infectious human papillomavirus type 18 pseudovirions.

Y Stauffer1, K Raj, K Masternak, P Beard.   

Abstract

Human papillomavirus type 18 (HPV18) capsid proteins L1 and L2, synthesised in mammalian cells using recombinant vaccinia viral expression vectors, are transported to the nucleus and assembled into virus-like particles. When 293T cells, which express SV40 T antigen, were transfected with plasmid DNAs containing an SV40 origin of replication then infected with vaccinia viral vectors encoding L1 and L2, plasmid DNA was encapsidated into the particles. The DNAs ranged in size from 5.4 to 7.9 kb. By encapsidating plasmids containing either the beta-galactosidase gene or the puromycin-resistance gene, the pseudovirions were shown to be infectious in that they could transfer beta-galactosidase activity or confer resistance to puromycin to a number of cell types, indicating that the uptake and decapsidation of HPV particles are not the main determinants of cell type specificity of HPV. Episomal HPV16 DNA in a cervical keratinocyte line could also be encapsidated. Further investigation showed that DNA encapsidation is independent of HPV DNA sequences and of T antigen-mediated plasmid DNA replication. Instead, the minor capsid protein, L2, was found to be attached to plasmid mini-chromosomes extracted from these cells, suggesting a role for L2 in encapsidation. Consistent with this, the L1 protein alone was unable to encapsidate DNA, although it was able to form virus-like particles. The results suggest that intracellular episomal DNAs of suitable size can be encapsidated by the HPV18 L1 and L2 proteins without the need of any HPV packaging signal, and reintroduced into cells. Copyright 1998 Academic Press.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9784363     DOI: 10.1006/jmbi.1998.2113

Source DB:  PubMed          Journal:  J Mol Biol        ISSN: 0022-2836            Impact factor:   5.469


  27 in total

1.  DNA-induced structural changes in the papillomavirus capsid.

Authors:  C Fligge; F Schäfer; H C Selinka; C Sapp; M Sapp
Journal:  J Virol       Date:  2001-08       Impact factor: 5.103

2.  Positively charged termini of the L2 minor capsid protein are necessary for papillomavirus infection.

Authors:  R B Roden; P M Day; B K Bronzo; W H Yutzy; Y Yang; D R Lowy; J T Schiller
Journal:  J Virol       Date:  2001-11       Impact factor: 5.103

3.  Assembly and translocation of papillomavirus capsid proteins.

Authors:  Luise Florin; Cornelia Sapp; Rolf E Streeck; Martin Sapp
Journal:  J Virol       Date:  2002-10       Impact factor: 5.103

4.  Identification of amino acid residues within simian virus 40 capsid proteins Vp1, Vp2, and Vp3 that are required for their interaction and for viral infection.

Authors:  Akira Nakanishi; Akiko Nakamura; Robert Liddington; Harumi Kasamatsu
Journal:  J Virol       Date:  2006-09       Impact factor: 5.103

5.  The minor capsid protein L2 contributes to two steps in the human papillomavirus type 31 life cycle.

Authors:  Sigrid C Holmgren; Nicole A Patterson; Michelle A Ozbun; Paul F Lambert
Journal:  J Virol       Date:  2005-04       Impact factor: 5.103

6.  Maturation of papillomavirus capsids.

Authors:  Christopher B Buck; Cynthia D Thompson; Yuk-Ying S Pang; Douglas R Lowy; John T Schiller
Journal:  J Virol       Date:  2005-03       Impact factor: 5.103

7.  A membrane-destabilizing peptide in capsid protein L2 is required for egress of papillomavirus genomes from endosomes.

Authors:  Nadine Kämper; Patricia M Day; Thorsten Nowak; Hans-Christoph Selinka; Luise Florin; Jan Bolscher; Lydia Hilbig; John T Schiller; Martin Sapp
Journal:  J Virol       Date:  2006-01       Impact factor: 5.103

8.  The transcription factors TBX2 and TBX3 interact with human papillomavirus 16 (HPV16) L2 and repress the long control region of HPVs.

Authors:  Marc A Schneider; Konstanze D Scheffer; Timo Bund; Fatima Boukhallouk; Carsten Lambert; Cristina Cotarelo; Gert O Pflugfelder; Luise Florin; Gilles A Spoden
Journal:  J Virol       Date:  2013-02-06       Impact factor: 5.103

9.  Detection of human papillomavirus type 31-neutralizing antibodies from naturally infected patients by an assay based on intracellular assembly of luciferase-expressing pseudovirions.

Authors:  Maxime J J Fleury; Antoine Touzé; Silvia de Sanjosé; F Xavier Bosch; Joellen Klaustermeiyer; Pierre Coursaget
Journal:  Clin Vaccine Immunol       Date:  2007-11-07

10.  Establishment of papillomavirus infection is enhanced by promyelocytic leukemia protein (PML) expression.

Authors:  Patricia M Day; Carl C Baker; Douglas R Lowy; John T Schiller
Journal:  Proc Natl Acad Sci U S A       Date:  2004-09-21       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.